TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 13.8nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection
of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of
phosp...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.8nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 20.8nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 22.3nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection
of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of
phosp...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 23.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 23nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 24.9nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection
of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of
phosp...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 32.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 32.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 34.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 34.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 35.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 35.7nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 36.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 36.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.3nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection
of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of
phosp...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 37.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 39.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 47.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 47.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 50.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 50.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 51.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 52.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 52.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 53.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 60.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 62.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 63.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 63.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 65.5nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 65.5nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 70.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 70.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 72nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair